Active, Not Recruiting
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) - CA209-010
Updated: 26 August, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component - Previous treatment with at least one anti-angiogenic agent - Progressed within 6 months of study enrollment - Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease - Must have available tumor tissue for submission - Subjects must also meet various laboratory parameters for inclusion Exclusion Criteria: - Subjects with any active autoimmune disease or a history of known autoimmune disease
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
